A fully humanised anti-Toll-like Receptor 2 (TLR2) antibody having bindingspecificity to TLR2 is provided wherein the antibody does not generateunwantedimmune responses when administered to humans. The antibody may comprise alight chain variable region of SEQ ID NO:1 and a heavy chain variable regionofSEQ ID NO:4. Advantageously, the antibody and antigen binding fragmentsthereof antagonise TLR2 independently of binding of the antibody or antigenbinding fragment to CD32. Also provided are nucleic acids encoding suchantibodies, as well as the use of the antibodies or antigen binding fragmentsthereof in medicine, in particular for the treatment of inflammatory andautoimmune diseases which are mediated by Toll-like Receptor 2 activation andsignalling.
